A method of manipulating allogeneic cells for use in allogeneic cell therapyprotocols is described. The method provides a composition of highly activatedallogeneic T-cells which are infused into immunocompetent cancer patients toelicit a novel anti-tumor immune mechanism called the "Mirror Effect". Incontrast to current allogeneic cell therapy protocols where T-cells in thegraft mediate the beneficial graft vs. tumor (GVT) and detrimental graft vs.host (GVH) effects, the allogeneic cells of the present invention stimulatehost T-cells to mediate the "mirror" of these effects. The mirror of the GVTeffect is the host vs. tumor (HVT) effect. The "mirror" of the GVH effect isthe host vs. graft (HVG) effect. The effectiveness and widespread applicationof the anti~tumor GVT effect is limited by the severe toxicity of the GVHeffect. In the present invention, the anti-tumor HVT effect occurs inconjunction with a non~ toxic HVG rejection effect. The highly activatedallogeneic cells of the invention can be used to stimulate host immunity in acomplete HLA mis~matched setting in patients that have not had a prior bonemarrow transplant or received chemotherapy and/or radiation conditioningregimens.
